CDC-RFA-CK-25-0144: Creutzfeldt-Jakob Disease (CJD) Increasing Educational Support for CJD Families and the Nation
Closed
This grant is closed. A newer notice from the same program is forecast: Continuing Enhanced National Surveillance for Prion Diseases in the United States (CDC-RFA-CK-27-0046). Status: Expected deadline March 27, 2027. It is in our archive of Centers for Disease Control - NCEZID notices from 2025.
Centers for Disease Control - NCEZID offered grants of up to $100,000 (at least $75,000) to any type of organization. It expected to make one award worth $500,000 in total. Applications closed on March 18, 2025.
From the official notice on Grants.gov, last changed January 17, 2025. Checked November 7, 2026.
- Award ceiling$100,000
- Award floor$75,000
- Total funding$500,000
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | January 17, 2025 |
|---|---|
| Deadline | March 18, 2025 |
| Archived by Grants.gov | April 17, 2025 |
Who can apply
This opportunity was open to any type of organization.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Eligible applicants include states, political subdivisions of states and other public and nonprofit private entities. The award ceiling for this NOFO is $100,000. CDC will consider any application requesting an award higher than this amount as non-responsive, and it will receive no further review.
Is this a realistic fit?
- Past Emerging Infections Programs awards averaged $2.5 million; this notice allows up to $100,000 per award.
- Most of the program's money (83% over five years) went to state and local governments.
- No cost sharing or match is required.
What the grant funds
Creutzfeldt-Jakob disease (CJD) is an incurable brain disorder that occurs with an incidence of one case per million annually. The majority of patients die within six months of illness onset. The disease causes damage to the brain leaving patients completely dependent on their caregivers for the most basic needs of daily living. In 1996, a variant form of CJD emerged in the United Kingdom, which was causally linked to bovine spongiform encephalopathy (BSE). Over 230 variant CJD cases have been identified worldwide, including four cases in the United States whose BSE exposure is believed based on epidemiological evidence to have occurred outside of the United States. This Notice of funding opportunity (NOFO) will help provide the latest information on human prion diseases to families of loved ones affected by these diseases as well as to public health service providers, other health professionals, and groups at highest risk for these diseases. Providing this information in a timely manner will strengthen efforts to more effectively monitor, to better understand and to ultimately reduce the incidence of those forms of prion diseases such as variant CJD that are preventable. It will also strengthen efforts to identify early the emergence of potentially new prion diseases in people such as possible human chronic wasting disease (CWD). In the United States, the ongoing prion disease outbreak among deer and elk called CWD continues to spread.
Who has won Emerging Infections Programs grants before
From fiscal 2021 to 2025, Emerging Infections Programs (93.317) awarded $514 million across 202 grant awards, an average of $2.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| State of Georgia Department of Public Health | Georgia | 4 | $35.8 million |
| Minnesota Department of Health | Minnesota | 5 | $35.6 million |
| Health Research, Inc. | New York | 4 | $32.2 million |
| Tennessee Department of Health | Tennessee | 5 | $30.8 million |
| Public Health Foundation Enterprises, Inc. | California | 3 | $28.6 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, CDC-RFA-CK-27-0046, which is forecast.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-CK-25-0144 still open?
No. It closed on March 18, 2025. A newer notice is forecast: CDC-RFA-CK-27-0046, expected deadline March 27, 2027.
Who can apply for Creutzfeldt-Jakob Disease (CJD) Increasing Educational Support for CJD Families and the Nation?
Centers for Disease Control - NCEZID accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Creutzfeldt-Jakob Disease (CJD) Increasing Educational Support for CJD Families and the Nation?
Closed March 18, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $100,000 each. About $500,000 in total for one award.
Who has won Emerging Infections Programs grants before?
The largest recipients over five fiscal years were State of Georgia Department of Public Health, Minnesota Department of Health, Health Research, Inc. The program made 202 awards worth $514 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)